Clinical trials: Influenza A
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects
This clinical trial is a phase 1/2 study of a single intramuscular injection of TAK-850 in healthy Japanese adult participants
- Trial name
- NCT02111252
- Testing
- TAK-850
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Avian Influenza, Influenza Immunisation
2017 A/H7N9 IIV Revaccination
This is a Phase II clinical trial in up to 420 males and non-pregnant females, 19 to 70 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03738241
- Testing
- A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
- Where
- 9 sites in United States
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Pandemic Influenza Prevention
A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.
- Trial name
- NCT03370289
- Testing
- BLB-750 Vaccine (Qinghai RG strain)
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children.
- Trial name
- NCT00972816
- Testing
- MF59-eH1N1
- Where
- 35 sites in United States, Mexico
- Volunteers
- 1,357 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic Influenza
A/H5N1/LT Dose Ranging Study
This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this study.
- Trial name
- NCT00908687
- Testing
- A/H5N1, LT Adjuvant Patch
- Where
- 6 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Influenza
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to Havrix®, a licensed Hepatitis A virus vaccine.
- Trial name
- NCT01218308
- Testing
- FluLaval® Quadrivalent, Havrix™
- Where
- 12 sites in Bangladesh, Dominican Republic and 6 more
- Volunteers
- 5,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly…
- Trial name
- NCT02369341
- Testing
- Fluarix Tetra
- Where
- 2 sites in Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Cold
The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.
This phase IV multi-centre, randomised, double-blind, placebo-controlled, parallel-group, single-dose study will assess the efficacy and tolerability of the active tablets versus placebo in participants suffering from cold and…
- Trial name
- NCT02246166
- Testing
- Test tablet
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- GlaxoSmithKline
Avian Influenza, H1N1 Influenza
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and…
- Conditions
- Avian Influenza, H1N1 Influenza, Influenza
- Trial name
- NCT02921997
- Testing
- AS03, Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203, Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, COVID-19
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
- Trial name
- NCT05858450
- Testing
- Comirnaty, Quadrivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 3,442,996 people
- Sponsor
- Pfizer
Influenza
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched control subjects .
- Trial name
- NCT01436370
- Testing
- Trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human
Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital
The purpose of this study is to determine whether zanamivir aqueous solution given by intravenous injection is safe in treating hospitalized patients with confirmed influenza infection.
- Trial name
- NCT01014988
- Testing
- zanamivir aqueous solution
- Where
- 110 sites in United States, Australia and 11 more
- Volunteers
- 202 people
- Sponsor
- GlaxoSmithKline
Influenza
Home Administration of FluMist by Parents/Caregivers
This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical…
- Trial name
- NCT01938170
- Testing
- FluMist
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Human Influenza
Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age
The present study is designed to confirm the safety and immunogenicity of trivalent, surface antigen, inactivated influenza vaccine including MF59C.1 adjuvant, formulation 2013/2014 Northern Hemisphere, in adults ≥65 years of…
- Trial name
- NCT01879540
- Testing
- aTIV
- Where
- Belgium
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza
A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults
The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1020, mRNA-1030, and mRNA-1010 vaccines against vaccine-matched influenza A and B strains.
- Trial name
- NCT05333289
- Testing
- mRNA-1030, mRNA-1020, mRNA-1010
- Where
- 15 sites in United States
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza Type A, Influenza Type B
Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants
Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc.
- Conditions
- Influenza Type A, Influenza Type B, Influenza
- Trial name
- NCT04471038
- Testing
- SAB-176, Normal Saline
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza
Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
1. To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level delivered i.m., or the 2.0 µg dose level delivered s.c.
- Trial name
- NCT00921947
- Testing
- VAX102
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation